TD Asset Management Inc Trims Position in Pfizer Inc. $PFE

TD Asset Management Inc decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,649,637 shares of the biopharmaceutical company’s stock after selling 28,692 shares during the period. TD Asset Management Inc owned approximately 0.06% of Pfizer worth $92,993,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Fiduciary Alliance LLC lifted its position in shares of Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Pfizer in the 3rd quarter valued at about $3,019,000. Money Concepts Capital Corp raised its stake in Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Vista Investment Partners LLC lifted its holdings in Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its stake in shares of Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to the BRAFTOVI (encorafenib) combination regimen for first‑line metastatic colorectal cancer with BRAF V600E mutation — a label expansion based on the Phase 3 BREAKWATER trial that de‑risks and commercializes a late‑stage oncology asset, supporting potential incremental sales and long‑term oncology upside. U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
• Positive Sentiment: Pfizer inks a China commercialization/licensing deal for Sciwind’s ecnoglutide (a next‑gen biased GLP‑1) with up to ~$495M in potential payments — accelerates Pfizer’s obesity/diabetes footprint in a large market and signals management’s push into metabolic medicines beyond acquisitions. Pfizer in diabetes drug deal with Sciwind Biosciences
• Positive Sentiment: Pipeline momentum: coverage notes highlight BREAKWATER results plus expanded obesity programs (Metsera acquisition and >20 weight‑management studies) — suggests diversification of future growth drivers beyond legacy products. Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
• Positive Sentiment: Dividend support: coverage reiterates Pfizer’s high dividend yield (attractive income for some investors) and management’s commitment to the payout, which can cushion the stock in choppy markets. This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
• Neutral Sentiment: Pneumococcal vaccine Phase 1 update in China — an early‑stage readout that is informational for the pipeline but unlikely to move top‑line revenue in the near term. Pfizer’s Pneumococcal Vaccine Study in China: What the Latest Trial Update Means for PFE Investors
• Neutral Sentiment: Valuation and performance write‑ups debate whether PFE is offering value after mixed multi‑year returns — useful context for long‑term investors but not an immediate catalyst. Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance
• Negative Sentiment: Pfizer terminated a Phase 1b ulcerative colitis study — a setback for that early‑stage program and a reminder of R&D risk; impact on revenue is limited but it trims future optionality in immunology. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study: What Investors Should Watch
• Negative Sentiment: Analyst caution: commentary that Pfizer has underperformed the healthcare sector over the past year could pressure sentiment and limit upside until clearer organic growth or margin inflection is visible. Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Analysts Set New Price Targets

A number of research firms have recently weighed in on PFE. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. Bank of America dropped their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.70.

Pfizer Trading Down 0.1%

PFE stock opened at $27.11 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market cap of $154.11 billion, a price-to-earnings ratio of 19.93 and a beta of 0.47. The business has a fifty day simple moving average of $26.04 and a 200-day simple moving average of $25.37. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.